Literature DB >> 11991133

Monte Carlo-aided dosimetry of the theragenics TheraSeed model 200 103Pd interstitial brachytherapy seed.

James I Monroe1, Jeffrey F Williamson.   

Abstract

A dosimetric study of a 103Pd seed for permanent interstitial brachytherapy, the Theragenics Corporation Model 200 (TheraSeed), has been undertaken utilizing Monte Carlo photon-transport (MCPT) simulations. All dosimetric quantities recommended by the American Association of Physicists in Medicine (AAPM) Task Group 43 (TG-43) [Med. Phys. 22, 209-234 (1995)] report have been calculated. This source contains graphite pellets coated with palladium metal, within which the radioactive 103Pd is distributed. Due to the significant influence of this metal coating thickness on the dose distribution, two coating thicknesses, 2.2 microm (light seed, representing currently available seeds) and 10.5 microm (heavy seed, representing reactor-produced seeds available before 1994), were analyzed. Quantities determined are the following: dose rate constant, radial dose function, anisotropy function, anisotropy factor, anisotropy constant, and "along and away" dose tables. The National Institute of Standards and Technology (NIST) Wide Angle Free Air Chamber (WAFAC) standard for air-kerma strength (SK,N99) was simulated, allowing a comparison to measured dosimetry data normalized to SKN99. The calculated dose-rate constants are 0.691 (light seed) and 0.694 cGy h(-1) U(-1) (heavy seed), where 1 U= 1 microGy x m2 x h(-1), in contrast to the recommended TG-43 value of 0.74 cGy h(-1) U(-1) and the value, 0.665 cGy h(-1) U(-1), recommended by AAPM report 69 [Med. Phys. 27, 634-642 (2000)]. Anisotropy constants (1/r2 weighted average, r > or = 1 cm) are 0.862 and 0.884 for the light seed and heavy seed, respectively. A generalization of the AAPM formalism [Med. Phys. 27, 634-642] for evaluating the time-dependent ratio of an administered-to-prescribed dose is presented. The findings of this study, in combination with 5% corrections applied to WAFAC measurements performed in 1999, imply that changes in the AAPM's recommended ratios as large as 6%, are indicated.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11991133     DOI: 10.1118/1.1460876

Source DB:  PubMed          Journal:  Med Phys        ISSN: 0094-2405            Impact factor:   4.071


  6 in total

1.  Comparison of dose calculation methods for brachytherapy of intraocular tumors.

Authors:  Mark J Rivard; Sou-Tung Chiu-Tsao; Paul T Finger; Ali S Meigooni; Christopher S Melhus; Firas Mourtada; Mary E Napolitano; D W O Rogers; Rowan M Thomson; Ravinder Nath
Journal:  Med Phys       Date:  2011-01       Impact factor: 4.071

2.  On the feasibility of polyurethane based 3D dosimeters with optical CT for dosimetric verification of low energy photon brachytherapy seeds.

Authors:  Justus Adamson; Yun Yang; Titania Juang; Kelsey Chisholm; Leith Rankine; John Adamovics; Fang Fang Yin; Mark Oldham
Journal:  Med Phys       Date:  2014-07       Impact factor: 4.071

3.  Evaluation of hypothetical (153)Gd source for use in brachytherapy.

Authors:  Mahdi Ghorbani; Marziyeh Behmadi
Journal:  Rep Pract Oncol Radiother       Date:  2015-06-27

4.  Fast patient-specific Monte Carlo brachytherapy dose calculations via the correlated sampling variance reduction technique.

Authors:  Andrew Sampson; Yi Le; Jeffrey F Williamson
Journal:  Med Phys       Date:  2012-02       Impact factor: 4.071

5.  Palladium-103 plaque radiation therapy for macular degeneration: results of a 7 year study.

Authors:  P T Finger; Y P Gelman; A M Berson; A Szechter
Journal:  Br J Ophthalmol       Date:  2003-12       Impact factor: 4.638

6.  Cylindrical coordinate based TG-43U1 parameters for dose calculation around elongated brachytherapy sources.

Authors:  Shahid B Awan; Sharifeh A Dini; Manzoor Hussain; David Soleimani-Meigooni; Ali S Meigooni
Journal:  J Appl Clin Med Phys       Date:  2008-04-16       Impact factor: 2.102

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.